Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Upcoming wave of hormone based therapies set to change field of diabetes, obesity care Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Mazdutide Bulk Supply buy from factory 99% Purity powder